460 completed, 129 unknown, 88 recruiting, 63 active not recruiting. 858 Phase 3, 76 Phase 2.
Follow Breast Cancer: new trials by email Literature Review of Breast Cancer trials Research Report on Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) Radiation Therapy, Standard of Care Radiation Therapy, No Intervention - Breast Cancer | Phase 3 | Not yet recruiting | NRG Oncology | 5270 | 2027-01-30 | 2026-09-30 |
| Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan Dexamethasone, antiemetic premedication, T-DXd - Breast Cancer, Interstitial Lung Disease (ILD) | Phase 3 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 244 | 2026-12-20 | 2026-10-19 |
| A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer HRS-6209 + Letrozole, Dalpciclib/Palbociclib + Letrozole/Anastrozole - Breast Cancer | Phase 3 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 1050 | 2026-11-20 | 2026-10-26 |
| Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority Study of Placebo vs Cefazolin Cefazolin 2 g Infusion, Placebo infusion of .9 normal saline - Breast Cancer, Breast Surgery | Phase 3 | Not yet recruiting | University Hospital, Clermont-Ferrand | 1600 | 2026-11-01 | 2026-10-27 |
| An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC SHR- A1811, SHR-A1811+BEV - Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 3 | Not yet recruiting | Fudan University | 140 | 2026-10-01 | 2026-06-25 |
| An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC SHR- A1811+ eve, SHR- A1811 - Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 3 | Not yet recruiting | Fudan University | 180 | 2026-10-01 | 2026-08-12 |
| JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer JYP0035 plus Fulvestrant, JYP0035 placebo plus Fulvestrant - Breast Cancer | Phase 3 | Not yet recruiting | Chengdu JOYO pharma Co., Ltd. | 171 | 2026-09-30 | 2026-08-25 |
| Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy Hyperbaric oxygen treatment, Standard Care (in control arm) - Breast Cancer, CIPN - Chemotherapy-Induced Peripheral Neuropathy | Phase 2 / Phase 3 | Recruiting | Guangdong Provincial People's Hospital | 160 | 2026-09-29 | 2026-09-30 |
| Effects, Metabolic Mechanisms and Predictors of Response to Acupuncture in Treating Psychoneurological Symptoms Among Breast Cancer Survivors Acupuncture, Sham acupuncture - Breast Cancer | Phase 3 | Not yet recruiting | University of Illinois at Chicago | 252 | 2026-09-01 | 2026-07-13 |
| NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy - Breast Cancer, Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Women's Cancer Study Group GmbH | 765 | 2026-08-30 | 2026-08-05 |
| Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy Aromatherapy, Standard triple antiemetic therapy - Breast Cancer, Aromatherapy | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 374 | 2026-08-18 | 2026-08-12 |
| Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment Creatine, Placebo - Breast Cancer | Phase 3 | Not yet recruiting | D'Or Institute for Research and Education | 227 | 2026-08-01 | 2026-01-28 |
| Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early Breast Cancer Whole Breast Irradiation, Partial Breast Irradiation - Breast Cancer, Node-negative Breast Cancer | Phase 3 | Not yet recruiting | Samsung Medical Center | 520 | 2026-08-01 | 2026-08-11 |
| A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel - Breast Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 446 | 2026-07-06 | 2026-07-23 |
| Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy SHR- A1811, PCbHP, SHR- A1811+ Pyrotinib - Breast Cancer | Phase 3 | Recruiting | Fudan University | 280 | 2026-05-06 | 2026-07-08 |
| The Comparison Between DEDTI BR and T/E BR Delayed endoscopic direct-to-implant breast reconstruction, Two-stage expander-to-implant breast reconstruction - Breast Cancer | Phase 3 | Not yet recruiting | West China Hospital | 412 | 2026-05-01 | 2026-05-18 |
| Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC Elacestrant, Standard-of-care endocrine treatment - Breast Cancer, HR+/HER2- Breast Cancer | Phase 3 | Recruiting | Women's Cancer Study Group GmbH | 1520 | 2026-04-29 | 2026-08-07 |
| The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER Individual dose of tamoxifen, Standard adjuvant therapy of tamoxifen - Breast Cancer, Adjuvant Drug Therapy | Phase 3 | Recruiting | Karolinska Institutet | 1100 | 2026-04-14 | 2026-08-12 |
| CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon） Dalpiciclib+AI ± OFS, TC (Docetaxel + Cyclophosphamide) × 4 cycles- endocrine therapy - Breast Cancer | Phase 3 | Recruiting | Fudan University | 2288 | 2026-04-03 | 2026-09-28 |
| Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction hypofractionated radiotherapy, conventional fractionated radiotherapy - Breast Cancer, Breast Reconstruction | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 506 | 2026-03-27 | 2026-06-22 |
Showing 20 of 858. Sign in to see all of them.
Breast Neoplasms (858) · Neoplasm Metastasis (40) · Neoplasms (21) · Triple Negative Breast Neoplasms (19) · Breast Neoplasms, Male (15) · Prostatic Neoplasms (14) · Carcinoma, Intraductal, Noninfiltrating (13) · Lung Neoplasms (12) · Neutropenia (11) · Pain (11) · Breast Carcinoma In Situ (10) · Fatigue (10) · Hot Flashes (10) · Motor Activity (10) · Depression (9)
Skin Diseases (858) · Skin and Connective Tissue Diseases (858) · Neoplasms by Site (856) · Breast Diseases (851) · Neoplasms (837) · Pathological Conditions, Signs and Symptoms (111) · Pathologic Processes (69) · Signs and Symptoms (48) · Neoplastic Processes (42) · Neoplasms by Histologic Type (38) · Urogenital Diseases (32) · Genital Diseases (31) · Neoplasms, Glandular and Epithelial (28) · Carcinoma (25) · Nervous System Diseases (25)
Cyclophosphamide (134) · Docetaxel (110) · Tamoxifen (86) · Paclitaxel (82) · Epirubicin (74) · Capecitabine (73) · Trastuzumab (73) · Doxorubicin (63) · Letrozole (61) · Fluorouracil (59) · Anastrozole (51) · Radiotherapy (50) · exemestane (37) · Fulvestrant (34) · Carboplatin (30)
Hoffmann-La Roche (39) · Fudan University (32) · AstraZeneca (27) · Alliance for Clinical Trials in Oncology (26) · Novartis Pharmaceuticals (20) · SWOG Cancer Research Network (18) · NSABP Foundation Inc (16) · ETOP IBCSG Partners Foundation (15) · GBG Forschungs GmbH (12) · M.D. Anderson Cancer Center (12) · The Netherlands Cancer Institute (10) · European Organisation for Research and Treatment of Cancer - EORTC (9) · Spanish Breast Cancer Research Group (9) · Sun Yat-sen University (9) · NCIC Clinical Trials Group (8)
United States (265) · China (182) · Canada (148) · United Kingdom (145) · France (143) · Italy (132) · Germany (127) · Spain (115) · Belgium (95) · Australia (90) · South Korea (85) · Brazil (82) · Poland (82) · Hungary (75) · Taiwan (71)
Norman Wolmark, MD (14) · Dimitris Mavrudis, MD (7) · James N. Ingle, MD (7) · Edith A. Perez, MD (6) · Helena Earl, MBBS, PhD, FRCP (5) · Paul E. Goss, MD, PhD (5) · Charles L. Loprinzi, MD (4) · Dawn Hershman, MD (4) · Debra Barton, RN, PhD, AOCN, FAAN (4) · Jin Zhang, Professor (4)
PMID 38979716, PMID 34037241, PMID 29522361, PMID 40207789, PMID 22508812, PMID 26101239, PMID 33853037, PMID 37338729, PMID 38335467, PMID 15172146, PMID 17236771, PMID 20138809, PMID 21128114, PMID 21376385, PMID 21880792, PMID 21937232, PMID 22437872, PMID 23054107, PMID 23504141, PMID 24002511, PMID 24472478, PMID 26276354, PMID 26840494, PMID 27264120, PMID 27557300, PMID 28379421, PMID 35462754, PMID 35594464, PMID 37207306, PMID 38442809, PMID 38913933, PMID 39621968, PMID 41980703, PMID 10076721, PMID 10076722, PMID 10458221, PMID 10663329, PMID 11286848, PMID 11416112, PMID 12048273, PMID 12149294, PMID 12196717, PMID 12243915, PMID 12419743, PMID 12490681, PMID 12636887, PMID 12668651, PMID 12804433, PMID 12814333, PMID 12957458
2005 (14), 2008 (12), 2023 (12), U10CA032102 (9), 2025 (7), U10CA037429 (7), 2009 (6), 2014 (6), 2017 (6), 2016 (5), 2018 (5), U10CA012027 (4), 2004 (3), 2015 (3), 2019 (3)